UBE2V1 and hepatocellular carcinoma: Therefore, targeted inhibition of UBE2V1 could disrupt this circuit, destabilize HIF-1α, and suppress its downstream pro-tumorigenic pathways, thereby providing a novel therapeutic strategy for hypoxic HCC that may overcome the current limitations of HIF inhibitors.